Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 27th March 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.

Issue 7, 2019
Previous Article Next Article

Investigations into the DNA-binding mode of doxorubicinone

Author affiliations


Cancer treatment is one of the major challenges facing the modern biomedical profession. Development of new small-molecule chemotherapeutics requires an understanding of the mechanism of action for these treatments, as well as the structure–activity relationship. Study of the well-known DNA-intercalating agent, doxorubicin, and its aglycone, doxorubicinone, was undertaken using a variety of spectroscopic and calorimetric techniques. It was found that, despite conservation of the planar, aromatic portion of doxorubicin, the agylcone does not intercalate; it instead likely binds to the DNA minor-groove.

Graphical abstract: Investigations into the DNA-binding mode of doxorubicinone

Back to tab navigation

Supplementary files

Publication details

The article was received on 21 Sep 2018, accepted on 31 Oct 2018 and first published on 31 Oct 2018

Article type: Paper
DOI: 10.1039/C8OB02344A
Citation: Org. Biomol. Chem., 2019,17, 1992-1998

  •   Request permissions

    Investigations into the DNA-binding mode of doxorubicinone

    S. S. Tartakoff, J. M. Finan, E. J. Curtis, H. M. Anchukaitis, D. J. Couture and S. Glazier, Org. Biomol. Chem., 2019, 17, 1992
    DOI: 10.1039/C8OB02344A

Search articles by author